Victoria M. Ettorre, DO, MS
Clinical AssociateAbout
Research
Publications
2026
1050 Association of p53 and p16 Expression Patterns with Mutational Landscapes in a Large Cohort of Endometrial Serous Carcinomas
Salehiazar S, Niu N, Ettorre V, Bellone S, Santin A, Hui P, Buza N. 1050 Association of p53 and p16 Expression Patterns with Mutational Landscapes in a Large Cohort of Endometrial Serous Carcinomas. Laboratory Investigation 2026, 106: 105340. DOI: 10.1016/j.labinv.2025.105340.Peer-Reviewed Original ResearchResponse to Wu et al. regarding “Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models”
Ettorre V, Buza N, Palmieri L, Santin A. Response to Wu et al. regarding “Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models”. International Journal Of Gynecological Cancer 2026, 104632. DOI: 10.1016/j.ijgc.2026.104632.Peer-Reviewed Original ResearchRemarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts
Palmieri L, Bellone S, Demirkiran C, Hartwich T, Sethi N, Ettorre V, Ottum S, Greenman M, Buza N, Hui P, Perrone E, Fanfani F, Fagotti A, Ratner E, Santin A. Remarkable preclinical activity of trastuzumab-deruxtecan (T-DXd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. Gynecologic Oncology 2026, 206: 65-73. PMID: 41690203, DOI: 10.1016/j.ygyno.2026.02.004.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 2T-DXdAntibody-drug conjugatesPreclinical activityEndometrial cancer patientsLow HER2 expressionFISH-negativeXenograft mouse modelTrastuzumab deruxtecanHER2 expressionCell linesHuman epidermal growth factor receptor 2 expressionCancer patientsMouse modelEpidermal growth factor receptor 2In vivoIn vitroAntibody-dependent cell cytotoxicityControl ADCEndometrial cancer cell linesHER2-overexpressing tumorsEffective treatment optionTumor growth suppressionHER2-lowStandard chemotherapyRemarkable preclinical activity of trastuzumab-deruxtecan (T-dxd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts
Palmieri L, Bellone S, Demirkiran C, Sethi N, Ottum S, Ettorre V, Greenman M, Hartwich T, Buza N, Hui P, Perrone E, Fanfani F, Fagotti A, Santin A. Remarkable preclinical activity of trastuzumab-deruxtecan (T-dxd) in FISH-negative, HER2 IHC 1+ and 2+ expressing primary endometrial cancer cell lines and xenografts. International Journal Of Gynecological Cancer 2026, 36: 103013. DOI: 10.1016/j.ijgc.2025.103013.Peer-Reviewed Original ResearchIntegrated mutational landscape analysis of endometrial stromal sarcoma
Hartwich T, Choi S, Hwang A, Bellone S, Palmieri L, Seo H, Kim T, Hong J, Krakstad C, Trovik J, Stefansson I, Haugland H, Greenman M, Ettorre V, Ottum S, Demirkiran C, Yang-Hartwich Y, Buza N, Hui P, Lopez S, Cormio G, Ramunno M, Zito A, Perrone E, Fagotti A, Fanfani F, Santoro A, Ravaggi A, Bignotti E, Odicino F, Ardighieri L, Ratner E, Angioli R, Perrone G, Luvero D, Conca B, Choi J, Schlessinger J, Santin A. Integrated mutational landscape analysis of endometrial stromal sarcoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2026, 123: e2531105123. PMID: 41591910, PMCID: PMC12867622, DOI: 10.1073/pnas.2531105123.Peer-Reviewed Original ResearchConceptsEndometrial stromal sarcomaHG-ESSStromal sarcomaLG-ESSFrequent lossMolecular basisHigh-gradeLow-gradePrediction of immunotherapy responseLoss of cell cycle regulationCell cycle regulationComplex DNA rearrangementsRare uterine malignancyCombination of MEKMutational landscape analysisDriver of malignancyTargeted treatment strategiesWhole genomeDNA rearrangementsFAK inhibitionTranscriptome sequencingWhole exomeGenetic landscapeChromosomal gainsRegulated genes
2025
Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report
Ettorre V, Palmieri L, Ottum S, Greenman M, Santin A. Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report. Gynecologic Oncology Reports 2025, 63: 102011. PMID: 41561674, PMCID: PMC12813050, DOI: 10.1016/j.gore.2025.102011.Peer-Reviewed Original ResearchLow grade serous ovarian cancerA Case ReportMEK inhibitorsAromatase inhibitorsTreatment optionsMultiple lines of chemotherapyBackground treatmentMEK inhibitor binimetinibDose-limiting toxicityLines of chemotherapyLong lasting responsesSerous ovarian cancerStandard treatment optionOral drug combinationsNovel treatment optionsMEK-162CA-125Partial responseDose reductionOvarian cancerPlatinum resistanceKRAS mutationsTargeted therapyDrug combinationsProlonged responseFolate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models
Ettorre V, Conca B, Demirkiran C, Bellone S, Sethi N, Hartwich T, Niu N, Buza N, Angioli R, Plotti F, Palmieri L, Santin A. Folate receptor alpha as a successful biomarker in the treatment of low-grade serous ovarian cancer patients using preclinical and clinical models. International Journal Of Gynecological Cancer 2025, 36: 102779. PMID: 41411700, DOI: 10.1016/j.ijgc.2025.102779.Peer-Reviewed Original ResearchLGSOC patientsLow-grade serous ovarian cancerSerous ovarian cancer patientsOvarian cancer patientsPatient-derived xenograft modelsSerous ovarian cancerMirvetuximab soravtansineStandard treatment modalityOvarian cancerFOLR1 expressionCancer patientsXenograft modelTreatment modalitiesRecurrent low-grade serous ovarian cancersResistant to standard treatment modalitiesClinical activitySerous ovarian cancer casesEpithelial ovarian cancer subtypesSevere combined immunodeficient miceProlonged partial responseOvarian cancer casesMEK inhibitor treatmentOvarian cancer subtypesMonths of treatmentResistance to chemotherapyA PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER
Santin A, Roque D, Siegel E, Ettorre V, Greenman M, Mcnamara B, Papatla K, Kailasam A, Azodi M, Buza N, Clark M, Hui P, Altwerger G, Dottino P, Ratner E, Bellone S. A PHASE II EVALUATION OF THE EFFICACY AND SAFETY OF SACITUZUMAB GOVITECAN IN PATIENTS WITH RECURRENT UTERINE CANCER. International Journal Of Gynecological Cancer 2025, 35: 102143. DOI: 10.1016/j.ijgc.2025.102143.Peer-Reviewed Original ResearchSuccessful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report
Ettorre V, Greenman M, Palmieri L, Demirkiran C, Santin A. Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report. Cureus 2025, 17: e94784. PMID: 41257122, PMCID: PMC12620085, DOI: 10.7759/cureus.94784.Peer-Reviewed Original ResearchHigh-grade serous ovarian cancerAntibody-drug conjugate trastuzumab deruxtecanAntibody-drug conjugatesOvarian cancer patientsTrastuzumab deruxtecanSacituzumab govitecanPlatinum resistanceTreatment optionsCancer patientsHigh-grade serous ovarian cancer patientsRecurrent ovarian cancer patientsDose-limiting toxicityAbdominal tumor massSerous ovarian cancerLiver metastatic lesionsEffective treatment optionNovel treatment optionsSequential useCA-125Metastatic lesionsDose reductionClinical responseOvarian cancerTumor massAnti-HER2Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis
Ettorre V, Bellone S, Buza N, Hui P, Hartwich T, Demirkiran C, Greenman M, Sethi N, Palmieri L, Santin A. Immunohistochemistry, next generation sequencing (NGS), and whole exome sequencing concordance in HER2 testing in uterine serous carcinoma: a retrospective analysis. Gynecologic Oncology 2025, 202: 131-136. PMID: 41092695, DOI: 10.1016/j.ygyno.2025.09.017.Peer-Reviewed Original ResearchConceptsUterine serous carcinomaWhole-exome sequencingFluorescent-in-situ hybridizationNext generation sequencingHER2-positiveSerous carcinomaImmunohistochemistry stainingCorrelation of HER2HER2-Targeted TherapyHER2-targeted treatmentTissue blocksGeneration sequencingTreatment-eligible patientsComprehensive whole-exome sequencingEvaluation of patientsNext generation sequencing dataNext generation sequencing platformsFluorescence in situ hybridizationUSC patientsHER2 testingERBB2 amplificationHER2 expressionTherapeutic optionsRetrospective analysisHER2